Cheal, Sarah

Publications

Sort by

Co-Author Network

selected publications

Efficacy of HER2-Targeted Intraperitoneal ²²⁵Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Academic Article GET IT
Pretargeting: A Path Forward for Radioimmunotherapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2022 Review GET IT
Times cited: 6
Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular cancer therapeutics. 2021 Academic Article GET IT
Times cited: 2
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate chemistry. 2021 Academic Article GET IT
Times cited: 5
Correction to An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjugate chemistry. 2021 Article GET IT
Times cited: 1
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Comment GET IT
Times cited: 9
Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 2020 Academic Article GET IT
Times cited: 16
An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjugate chemistry. 2020 Academic Article GET IT
Times cited: 13
Pharmacokinetics and Biodistribution of a [⁸⁹Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. Molecular pharmaceutics. 2019 Academic Article GET IT
Times cited: 21
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 32
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics. 2018 Academic Article GET IT
Times cited: 26
ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Molecular pharmaceutics. 2018 Academic Article GET IT
Times cited: 5
Cancer-Targeting Ultrasmall Silica Nanoparticles for Clinical Translation: Physicochemical Structure and Biological Property Correlations. Chemistry of materials : a publication of the American Chemical Society. 2017 Academic Article GET IT
Times cited: 53
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 34
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 92
Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI research. 2016 Academic Article GET IT
Times cited: 56
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European journal of nuclear medicine and molecular imaging. 2015 Academic Article GET IT
Times cited: 33
Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. The Journal of biological chemistry. 2015 Academic Article GET IT
Times cited: 73
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 148
STAQ: A route toward low power, multicolor nanoscopy. Microscopy research and technique. 2015 Academic Article GET IT
Times cited: 2
Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014 Academic Article GET IT
Times cited: 23
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2014 Academic Article GET IT
Times cited: 112
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 46
Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. European journal of nuclear medicine and molecular imaging. 2014 Academic Article GET IT
Times cited: 60
Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy. Molecular pharmaceutics. 2013 Academic Article GET IT
Times cited: 7
N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein. Bioconjugate chemistry. 2013 Academic Article GET IT
Times cited: 4
(18)F-labeled-bioorthogonal liposomes for in vivo targeting. Bioconjugate chemistry. 2013 Academic Article GET IT
Times cited: 70
Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integrative biology : quantitative biosciences from nano to macro. 2013 Academic Article GET IT
Times cited: 25
Imaging tumor burden in the brain with 89Zr-transferrin. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012 Academic Article GET IT
Times cited: 35
Development of a MR-visible compound for tracing neuroanatomical connections in vivo. Neuron. 2011 Academic Article GET IT
Times cited: 17
Mapping protein-protein interactions by localized oxidation: consequences of the reach of hydroxyl radical. Biochemistry. 2009 Academic Article GET IT
Times cited: 22
Cysteinylated protein as reactive disulfide: an alternative route to affinity labeling. Bioconjugate chemistry. 2007 Academic Article GET IT
Times cited: 6
Method to site-specifically identify and quantitate carbonyl end products of protein oxidation using oxidation-dependent element coded affinity tags (O-ECAT) and nanoliquid chromatography Fourier transform mass spectrometry. Journal of proteome research. 2006 Academic Article GET IT
Times cited: 50

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

DOTA-based pre-targeting of alpha emitters awarded by National Cancer Institute Principal Investigator 2022 - 2023

Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture awarded by National Institute of Diabetes & Digestive & Kidney Diseases Principal Investigator Subaward 2022 - 2026

more ...

less ...

Background

education and training

Ph.D., University of California, Davis 2008
B.S., California State Polytechnic University, San Luis Obispo 2001

Contact

full name

Sarah Cheal

primary email

smc4002@med.cornell.edu

VIVO Weill Cornell Medical College

Sarah Cheal Assistant Professor of Biological Chemistry in Radiology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email